Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial.

Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Anderson JL, Li J, Rodriguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple B, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby CS.

JAMA. 2019 Sep 3;322(9):834-842. doi: 10.1001/jama.2019.12085.

PMID:
31479138
2.

Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.

Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodríguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple BD, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby CS.

JAMA. 2017 Sep 26;318(12):1115-1124. doi: 10.1001/jama.2017.11469. Erratum in: JAMA. 2018 Mar 27;319(12 ):1281.

3.

Gamma-glutamyl carboxylase and its influence on warfarin dose.

King CR, Deych E, Milligan P, Eby C, Lenzini P, Grice G, Porche-Sorbet RM, Ridker PM, Gage BF.

Thromb Haemost. 2010 Oct;104(4):750-4. doi: 10.1160/TH09-11-0763. Epub 2010 Aug 5.

4.

Heparin and oversulfated heparin byproduct induce thrombin generation through contact system activation in plasma of patients with HIT.

Yi Qian, Jing Pan, Xiaodong Zhou, Weiser P, Hong Lu, Shih FF, Porche-Sorbet R, Eby C, Lijuan Zhang.

Clin Appl Thromb Hemost. 2010 Jun;16(3):251-60. doi: 10.1177/1076029610362072. Epub 2010 May 11.

PMID:
20460351
5.

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Patel SR, Cavallari LH, Ridker PM, Grice GR, Miller RD, Gage BF.

Clin Pharmacol Ther. 2010 Apr;87(4):445-51. doi: 10.1038/clpt.2009.291. Epub 2010 Mar 3.

6.

Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Lenzini PA, Grice GR, Milligan PE, Dowd MB, Subherwal S, Deych E, Eby CS, King CR, Porche-Sorbet RM, Murphy CV, Marchand R, Millican EA, Barrack RL, Clohisy JC, Kronquist K, Gatchel SK, Gage BF.

J Thromb Haemost. 2008 Oct;6(10):1655-62. doi: 10.1111/j.1538-7836.2008.03095.x. Epub 2008 Jul 24.

7.

Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.

King CR, Porche-Sorbet RM, Gage BF, Ridker PM, Renaud Y, Phillips MS, Eby C.

Am J Clin Pathol. 2008 Jun;129(6):876-83. doi: 10.1309/1E34UAPR06PJ6HML.

PMID:
18480003
8.

Population variation in VKORC1 haplotype structure.

Marsh S, King CR, Porche-Sorbet RM, Scott-Horton TJ, Eby CS.

J Thromb Haemost. 2006 Feb;4(2):473-4. No abstract available.

9.

Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method.

Halldórsdóttir AM, Stoker J, Porche-Sorbet R, Eby CS.

Clin Chem. 2005 Jun;51(6):1054-7. No abstract available.

10.

The role of the factor X activation peptide: a deletion mutagenesis approach.

Rudolph AE, Mullane MP, Porche-Sorbet R, Daust HA, Miletich JP.

Thromb Haemost. 2002 Nov;88(5):756-62.

PMID:
12428090
11.

Expression of the regenerating gene family in inflammatory bowel disease mucosa: Reg Ialpha upregulation, processing, and antiapoptotic activity.

Dieckgraefe BK, Crimmins DL, Landt V, Houchen C, Anant S, Porche-Sorbet R, Ladenson JH.

J Investig Med. 2002 Nov;50(6):421-34. doi: 10.1136/jim-50-06-02.

PMID:
12425429
12.

Definition of a factor Va binding site in factor Xa.

Rudolph AE, Porche-Sorbet R, Miletich JP.

J Biol Chem. 2001 Feb 16;276(7):5123-8. Epub 2000 Nov 21.

13.

Directed glycosylation of human coagulation factor X at residue 333. Insight into factor Va-dependent prothrombin catalysis.

Cook BC, Rudolph AE, Kurumbail RG, Porche-Sorbet R, Miletich JP.

J Biol Chem. 2000 Dec 8;275(49):38774-9.

14.

Substitution of asparagine for arginine 347 of recombinant factor Xa markedly reduces factor Va binding.

Rudolph AE, Porche-Sorbet R, Miletich JP.

Biochemistry. 2000 Mar 21;39(11):2861-7.

PMID:
10715105
15.

Expression, purification, and characterization of recombinant human factor X.

Rudolph AE, Mullane MP, Porche-Sorbet R, Miletich JP.

Protein Expr Purif. 1997 Aug;10(3):373-8.

PMID:
9268685
16.

Factor XSt. Louis II. Identification of a glycine substitution at residue 7 and characterization of the recombinant protein.

Rudolph AE, Mullane MP, Porche-Sorbet R, Tsuda S, Miletich JP.

J Biol Chem. 1996 Nov 8;271(45):28601-6.

Supplemental Content

Loading ...
Support Center